David King
Portfolio Manager, New Value Fund at Putnam Investments
Member since: Apr '04 · 4 Opinions
Rating Card
| All | 
Rating
| 
Big Win
| 
Win
| 
Neutral
| 
Loss
| 
Big Loss
|  |
|---|---|---|---|---|---|---|---|
| 0 | 0 0.00% | 0 0.00% | 0 0.00% | 0 0.00% | 0 0.00% |
Stock Opinions by David King
TOP PICK
A pure value buy. 9 X trailing PE and 3% yield is intriguing. Headline risk is not as important as were the numbers and up ultimately.
Financial Services
$68.710
Owned
TOP PICK
Betting on the franchise. Benefits from economic recovery on a global basis. Exciting product line with their iGen3. Still cheap.
misc industrial products
BUY
Attractive. Continuing turnaround in their diagnostic business as well as a better pipeline than some of the other chief pharmaceuticals.
biotechnology / pharmaceutical
BUY
A potential takeover play. Has been a bit undermanaged and is very cheap.
biotechnology / pharmaceutical
Showing 1 to 4
of 4 entries
- «
- ‹
- 1
- ›
- »
